相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Strand transfer inhibitors of HIV-1 integrase: Bringing IN new era of antiretroviral therapy
Damian J. McColl et al.
ANTIVIRAL RESEARCH (2010)
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
Roy T. Steigbigel et al.
CLINICAL INFECTIOUS DISEASES (2010)
Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and Maraviroc
Srinivasan Ramanathan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial
Andrew R. Zolopa et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine
Monika Scholler-Gyure et al.
CLINICAL PHARMACOKINETICS (2009)
Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression
S. Collot-Teixeira et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Emerging Pharmacology: Inhibitors of Human Immunodeficiency Virus Integration
Daria Hazuda et al.
Annual Review of Pharmacology and Toxicology (2008)
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers
Vanitha J. Sekar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc:: in vitro assessment of drug-drug interaction potential
Ruth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir
Anita A. Mathias et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Broad Antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
Kazuya Shimura et al.
JOURNAL OF VIROLOGY (2008)
HIV drug development: the next 25 years
Charles Flexner
NATURE REVIEWS DRUG DISCOVERY (2007)
Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
Srinivasan Ramanathan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged
Mary B. Wire et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers
D. M. Burger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir
Amanda H. Corbett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Practical perspectives on the use of tipranavir in combination with other medications: Lessons learned from pharmacokinetic studies
M Boffito et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation
DL Zhang et al.
DRUG METABOLISM AND DISPOSITION (2005)
The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations
SD Shafran et al.
HIV MEDICINE (2005)
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes
WP Yong et al.
CLINICAL CANCER RESEARCH (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
ADM Kashuba et al.
AIDS (2005)
Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients
M Boffito et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir
JQ Tran et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
分享论文
